SeroSelectTB - prosjektbeskrivelse
The performance of a new triage test for active tuberculosis, SeroSelectTB, will be qualified in multi-centre randomised controlled trials at health-posts in South Africa, Tanzania and Ethiopia. Cost effectiveness evaluations will be conducted to support a value proposition to stakeholders and regulatory authorities, and to support commercialization requirements. Consenting adults will provide blood and saliva samples for screening by SeroSelectTB, and sputum collected for routine TB diagnosis by the health services. Clinical and sociodemographic information will be collected. A reliable rapid test will make it possible to identify and selectively treat those with active TB at the local healthcare level. The expected impact includes accurate same-day diagnosis of patients with active TB, reduction of diagnostic delay and TB transmission, and diagnostic cost-savings for patients and healthcare systems in high burden countries.
Se fullstendig prosjektbeskrivelse på Cristin for mer informasjon om resultater, deltakere, kontakter med mer
Kidist Bobosha, AHRI Armauer Hansen Research Institute
Balthazar Nyombi, Kilimanjaro Christian Medical University College
Grant Theron, Universiteit van Stellenbosch / University of Stellenbosch
Kristin Kremer, Rijksinstituut voor Volksgezondheid en Milieu